CTLA4 and diffuse large B-cell lymphoma: These results confirm our hypothesis that, in most DLBCL patients, regardless of CAR T cell treatment, one or even both ligands for CTLA-4 are already upregulated on the surface of lymph node B and lymphoma cells.